Addressing the Challenges of Alzheimer’s Agitation
Advancing IGC-AD1 in the CALMA trial—supporting patients and caregivers through science and compassion.
Our Science, Our Commitment
What is CALMA?
CALMA is a multicenter Phase 2 clinical trial designed to evaluate the safety and potential efficacy of IGC-AD1 for treating agitation in participants with dementia due to Alzheimer's disease.
Explore CALMA →What is IGC-AD1?
IGC-AD1 is IGC Pharma’s lead candidate—a partial CB1 receptor agonist with anti-inflammatory action, designed to address agitation associated with Alzheimer’s disease.
Learn About IGC‑AD1 →Why AI Integration?
Our AI transforms multimodal data into actionable insights, empowering physicians with early Alzheimer’s prediction and more precise clinical decisión support.
Discover MINT‑AD →Latest Press Releases
Explore how IGC Pharma’s data, trials, and milestones are shaping a brighter future for Alzheimer’s care.
IGC Pharma Expands Phase 2 CALMA Trial into Colombia’s Premier Alzheimer’s Research Center
IGC Pharma Reaches 70% Enrollment in Phase 2 CALMA Trial Evaluating IGC-AD1 for Alzheimer’s Agitation
IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Trail Site at Integrative Clinical Trials in New York
IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Site at Dominion Medical Associates, a Lightship network site, in Richmond, Virginia
Together, we’re turning research into resilience, and innovation into care for millions worldwide.
0
Million
Americans projected to have Alzheimer’s disease by 2043
0
Million
Americans projected to have Alzheimer’s disease by 2060
0
th
Leading cause of death among Americans aged 65+
$
0
Trillion
Expected cost of Alzheimer’s and dementia by 2050 (in 2024 dollars) if no treatment or cure is found.
Pipeline
IGC Pharma’s pipeline bridges breakthroughs from AI-enhanced
early detection to IGC-AD1 and beyond, advancing Alzheimer’s
treatment frontiers.
In-depth insights,
real impact
“Science Spotlight” reveals our latest Alzheimer’s research, breakthroughs, and care innovations.
Resources
for Caregivers
This guide offers compassionate, evidence-based support for families caring for someone with Alzheimer’s disease. Written by leading neuropsychologists and enriched with real caregiver stories, it provides practical tips, emotional strategies, and step-by-step advice to understand the condition, manage daily challenges, and support emotional well-being. Supported by IGC Pharma, the book empowers caregivers with tips, strategies, and step-by-step guidance to improve care while also protecting their own well-being.
Investing in the Future:
IGC Pharma stands with families and vulnerable groups, investing in research, education, advocacy and Alzheimer’s awareness.
